{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:30:25Z","timestamp":1787841025303,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background and Objectives:<\/jats:title>\n                    <jats:p>Subacute sclerosing panencephalitis (SSPE) is a progressive disorder caused due to the persistence of mutant measles virus in the brain. Treatment strategies for SSPE remain largely undefined, and there exists no information on how neurologists are currently managing SSPE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A survey-based study was conducted among Indian neurologists managing pediatric and adult patients with SSPE. A questionnaire-based survey was circulated by email regarding respondent demographics, preference for disease-modifying strategies, and symptomatic therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Survey response was obtained from 298 neurologists (responder rate 9.5%) and eventually analyzed from 266 respondents who managed SSPE in routine practice. This included 222 (83.5%) adult and 44 (16.5%) pediatric neurologists from 21 states of India. Ninety-five respondents (35.7%) indicated that they always advised Isoprinosine (inosine pranobex) to their patients. Regarding interferon therapy, 121 (45.5%) reported never advising it, whereas 56 (21.1%) always advised it. For myoclonus, the most frequently used first-line drug was valproate (181, 68%), followed by levetiracetam (58, 21.8%). Most (150, 56.4%) of the respondents favored personalized therapy for the individual patient in terms of the duration of disease-modifying treatment. The patient follow-up was reported to be poor, with most (171, 64.3%) of the patients following up only occasionally and 24 (9%) respondents indicating that patients are lost to follow-up promptly after the initial visit.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>While SSPE remains a vaccine-preventable illness and the focus should be on prevention through vaccination, there is an unmet urgent need among Indian neurologists for better-defined treatment strategies for patients with SSPE.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_507_24","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T02:00:09Z","timestamp":1733450409000},"page":"684-689","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Contemporary Treatment Practices for Subacute Sclerosing Panencephalitis: A Nationwide Survey Among Adult and Pediatric Neurologists in India"],"prefix":"10.4103","volume":"27","author":[{"given":"Divyani","family":"Garg","sequence":"first","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Archita","family":"Makharia","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayush","family":"Agarwal","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Neuroimaging and Interventional Radiology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achal K","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Neurology, All India Institute of Medical Sciences, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"R1-20260424","doi-asserted-by":"crossref","first-page":"e2058","DOI":"10.1002\/rmv.2058","article-title":"Subacute sclerosing panencephalitis","volume":"29","author":"Garg","year":"2019","journal-title":"Rev Med Virol"},{"key":"R4-20260424","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.2020.14828","article-title":"Vaccine refusal and measles outbreaks in the US","volume":"324","author":"Phadke","year":"2020","journal-title":"JAMA"},{"key":"R5-20260424","doi-asserted-by":"crossref","first-page":"351","DOI":"10.17712\/nsj.2018.4.20180168","article-title":"Fulminant subacute sclerosing panencephalitis in an immunized 20-month-old Indian boy","volume":"23","author":"Khursheed","year":"2018","journal-title":"Neurosciences (Riyadh)"},{"key":"R6-20260424","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/PHMT.S126293","article-title":"Subacute sclerosing panencephalitis \u2013 Current perspectives","volume":"9","author":"Jafri","year":"2018","journal-title":"Pediatric Health Med Ther"},{"key":"R7-20260424","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1177\/08830738221085158","article-title":"Spectrum of movement disorders among children with subacute sclerosing panencephalitis: A cross-sectional study","volume":"37","author":"Garg","year":"2022","journal-title":"J Child Neurol"},{"key":"R8-20260424","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1002\/mdc3.14062","article-title":"Movement disorders in patients with subacute sclerosing panencephalitis: A systematic review","volume":"11","author":"Garg","year":"2024","journal-title":"Mov Disord Clin Pract"},{"key":"R9-20260424","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/aian.aian_655_22","article-title":"Disease-modifying therapy in subacute sclerosing panencephalitis: An area of darkness","volume":"26","author":"Garg","year":"2023","journal-title":"Ann Indian Acad Neurol"},{"key":"R10-20260424","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s11940-022-00710-x","article-title":"Options in the treatment of subacute sclerosing panencephalitis: Implications for low resource areas","volume":"24","author":"Samia","year":"2022","journal-title":"Curr Treat Options Neurol"},{"key":"R11-20260424","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.2196\/jmir.6.3.e34","article-title":"Improving the quality of web surveys: The checklist for reporting results of internet e-surveys (CHERRIES)","volume":"6","author":"Eysenbach","year":"2004","journal-title":"J Med Internet Res"},{"key":"R12-20260424","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/088307380301801201","article-title":"Randomized treatment study of inosiplex versus combined inosiplex and intraventricular interferon-alpha in subacute sclerosing panencephalitis (SSPE): International multicenter study","volume":"18","author":"Gascon","year":"2003","journal-title":"J Child Neurol"},{"key":"R13-20260424","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1212\/WNL.42.3.488","article-title":"Intraventricular interferon and oral inosiplex in the treatment of subacute sclerosing panencephalitis","volume":"42","author":"Yalaz","year":"1992","journal-title":"Neurology"},{"key":"R14-20260424","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1212\/WNL.48.2.526","article-title":"Long-term follow-up of patients with subacute sclerosing panencephalitis treated with intraventricular alpha-interferon","volume":"48","author":"Anlar","year":"1997","journal-title":"Neurology"},{"key":"R15-20260424","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/0387-7604(93)90120-W","article-title":"Combined oral isoprinosine-intraventricular alpha-interferon therapy for subacute sclerosing panencephalitis","volume":"15","author":"Gascon","year":"1993","journal-title":"Brain Dev"},{"key":"R16-20260424","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/ana.410290118","article-title":"Apparent response of subacute sclerosing panencephalitis to intrathecal interferon alpha","volume":"29","author":"Miyazaki","year":"1991","journal-title":"Ann Neurol"},{"key":"R17-20260424","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1651-2227.1985.tb10973.x","article-title":"Intrathecal administration of human leukocyte interferon to a patient with subacute sclerosing panencephalitis","volume":"74","author":"Nakagawa","year":"1985","journal-title":"Acta Paediatr Scand"},{"key":"R18-20260424","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ana.410190317","article-title":"Intrathecal interferon in subacute sclerosing panencephalitis","volume":"19","author":"Huttenlocher","year":"1986","journal-title":"Ann Neurol"},{"key":"R19-20260424","first-page":"1","article-title":"Role of carbamazepine in the symptomatic treatment of subacute sclerosing panencephalitis: A case report and review of the literature","volume":"2013","author":"Ravikumar","year":"2013","journal-title":"Case Rep Neurol Med"},{"key":"R20-20260424","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s10459-010-9222-y","article-title":"Likert scales, levels of measurement and the \u201claws\u201d of statistics","volume":"15","author":"Norman","year":"2010","journal-title":"Adv Health Sci Educ Theory Pract"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_507_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:39:09Z","timestamp":1787837949000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_507_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":18,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_507_24","relation":{},"ISSN":["0972-2327","1998-3549"],"issn-type":[{"value":"0972-2327","type":"print"},{"value":"1998-3549","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"2024-06-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-10-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}